{"disease":{"id":"bacterial-cystitis","name":"Bacterial cystitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"ceftolozane","indication_name":"Bacterial cystitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zerbaxa","generic_name":"CEFTOLOZANE","company_name":"Cubist Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":"Zerbaxa works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"tazobactam","indication_name":"Bacterial cystitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zosyn","generic_name":"TAZOBACTAM","company_name":"Merck Sharp & Dohme B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":50,"revenue":null,"mechanism":"Zosyn works by blocking bacterial enzymes that break down antibiotics, allowing the antibiotics to kill bacteria more effectively."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06284265","title":"Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":415,"lead_sponsor_name":"Materia Medica Holding","has_results":false},{"nct_id":"NCT06815549","title":"An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis\"","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":280,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}